Diverse Biotech
Dr. Friedman is world’s foremost expert in glioblastomas and Dep Director of Preston Robert Tisch Brain Tumor Ctr. He is involved in the treatment of over 900 glioblastoma patients per year. He was also instrumental in the FDA approval of Avastin which generated $56 Billion for Roche Pharma (2004-2017).
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Diverse Biotech
Diverse Biotech is an innovative, clinical-stage biopharmaceutical research company that is committed to discovering and developing novel therapeutics from its proprietary and patented cannabinoid formulations and cancer research.